Group 1 - The company expects to record a significant fair value loss of approximately RMB 16.3 million related to its investment in ERX Pharmaceuticals Inc. due to recent changes in the U.S. capital market environment [1] - The fair value loss is primarily attributed to a shift in investor funding towards AI and technology sectors, leading to a decline in financing activities for traditional drug development and clinical research [1] - The board believes that the fair value loss will not have any significant adverse impact on the company's existing business, operations, or financial condition, as the group's liquidity remains strong and overall financial and operational status is stable [1] Group 2 - The company reported a revenue of RMB 259 million for the first half of 2025, representing a year-on-year increase of 1.8% [1]
碧生源(00926.HK)：预计因投资ERX录得公允值亏损约1630万元